Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Call December 1, 2025 4:30 PM EST
Company Participants
David Campbell – President, CEO & Director
Conference Call Participants
Chad Rubin
Joshua Schimmer – Cantor Fitzgerald & Co., Research Division
Bradley Canino – Guggenheim Securities, LLC, Research Division
Marc Frahm – TD Cowen, Research Division
Matthew Phipps – William Blair & Company L.L.C., Research Division
Karina Rabayeva – Truist Securities, Inc., Research Division
Jeffrey LaRosa – Leerink Partners LLC, Research Division
Jonathan Miller – Evercore ISI Institutional Equities, Research Division
Presentation
Operator
Good afternoon. My name is Jeannie, and I will be your conference operator today. I would like to welcome you to the Janux Therapeutics Clinical Data Update Webcast. [Operator Instructions]
I would now like to turn the conference call over to Chad Rubin, Head of Investor Relations for Janux. You may begin your conference.
Chad Rubin
Thank you, Jeannie, and good afternoon, everyone. Today, Janux issued a press release announcing interim clinical data for the company’s JANX007 clinical program. This press release, today’s webcast and corresponding slides are available on our website.
Before we begin our prepared remarks, we would like to remind everyone that certain comments made by Janux management on this call will include forward-looking statements. These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in such statements. These and other risks and uncertainties are described in our periodic filings made with the SEC. You are cautioned not to place undue reliance on our forward-looking statements, and the company disclaims any obligation to update those statements.
With that, I would like to turn the call over to David Campbell, President and CEO of Janux.
David Campbell
President, CEO & Director
